ArticleSignal transduction and targeted therapy2026
Serpina3c protects against metabolic dysfunction-associated steatotic liver disease in offspring induced by prenatal prednisone exposure.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Prenatal antifungal exposure disrupts fetal steroidogenesis and is associated with persistent effects in children.Communications medicine · 2026Article
- miR-135a-5p Is a Promising Target to Prevent the Glomerulosclerosis Associated with Podocyte Developmental Toxicity in Offspring Induced by Prenatal Dexamethasone Exposure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major global public health problem, and its occurrence is associated with adverse environmental exposures during development. In this study, we investigated the impact of the use of prednisone (a synthetic glucocorticoid drug) during pregnancy on susceptibility to MASLD in offspring and explored its potential therapeutic targets. Pregnant rodents were administered clinically equivalent doses of prednisone daily by oral gavage during gestation days (GDs) 0-20 in rats and GD0-18 mice, and their offspring were fed a high-fat diet from postnatal weeks 8-12. The results showed that prenatal prednisone exposure (PPE) led to reduced hepatic glucose uptake and fatty acid oxidation in offspring rats prenatally and postnatally and that the offspring developed more severe MASLD when fed a high-fat diet, with males exhibiting greater severity than females. Consistent findings were observed in PPE adult offspring mice. RNA-seq and experimental results revealed that hepatic Serpina3c expression was consistently reduced in PPE offspring before and after birth, which led to an increase in chymase-Ang II production and subsequent activation of its receptor AT1R, leading to MASLD susceptibility. In vivo and in vitro studies revealed that the programming of low Serpina3c expression was associated with reduced H3K27ac levels in the gene promoter region of Serpina3c caused by the activation of GR-HDAC3 signaling by the active metabolite prednisolone. Finally, postnatal high expression of hepatic Serpina3c reversed the activation of the chymase-Ang II-AT1R pathway and significantly ameliorated hepatic glucose and lipid metabolic dysfunction and MASLD susceptibility in PPE offspring. In summary, this study reveals MASLD susceptibility in offspring induced by PPE and identifies Serpina3c as a target for the prevention and treatment of MASLD susceptibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.